Who is Kairat Bermukanov?
Kairat Bermukanov is the president of IBF TRUST , a hedge fund with a capitalization of $303 million and assets under management exceeding $150 million. In the fiscal years 2024–2025, the fund reported a return of +3939% .
Kairat Bermukanov is the president of IBF TRUST , a hedge fund with a capitalization of $303 million and assets under management exceeding $150 million. In the fiscal years 2024–2025, the fund reported a return of +3939% .
Mr. Bermukanov has a diverse background in finance and athletics. He was a professional judo athlete, achieving the rank of Master of Sports. He graduated with honors in law from the Novosibirsk Military Institute of the National Guard of Russia and holds a degree in "Coach-Teacher" from the Lesgaft Institute of Physical Culture and Sports (2016–2018). Furthering his education, he completed an MBA program in Finance and Economics (2018–2021) .
His financial career began during his academic years, focusing on asset analysis, risk management, and financial instruments. He is certified by the Federal Financial Markets Service of Russia .
Kairat Bermukanov is the president of IBF TRUST , a hedge fund with a capitalization of $303 million and assets under management exceeding $150 million.
Under Mr. Bermukanov's leadership, IBF TRUST employs advanced capital management strategies. The fund utilizes data from platforms like Bloomberg, Refinitiv, FactSet, S&P Capital IQ Pro, Nasdaq ITCH/LOBSTER, and XBRL aggregators . These resources provide comprehensive financial data, enabling the generation of various indicators related to price behavior, liquidity, and macroeconomic conditions. The fund operates under regulatory supervision in Dubai, where it holds the necessary licenses.
IBF TRUST engages in philanthropic activities, funding programs in children's sports, healthcare, and education. In 2024, it initiated an eco-village project in Europe and the "Clean Lungs" initiative in collaboration with Si14 holding , distributing nicotine-free e-cigarettes in the CIS.
The fund also supports Si14 AG Pharma in cancer treatment research, financed through its revenue.
Based on reporting by TechBullion.
